ZEUS Scientific is now Sebia Email Format

Hospitals and Health CareNew Jersey, United States11-50 Employees

ZEUS Scientific, now part of Sebia and based in Branchburg, New Jersey, develops clinical diagnostic systems designed to deliver efficient and accurate laboratory results. Its offering centers on autoimmune and infectious disease serology, with continued expansion into predictive cardiac biomarkers and other novel diagnostic tools. The first predictive cardiac biomarker in its lineup, AccuCardia, measures secreted phospholipase A2-IIA (sPLA2-IIA) in human plasma to support cardiovascular risk assessment beyond conventional markers. The company emphasizes dependable performance and ease of use to support patient care across standard diagnostic workflows.

Operating in the hospital and health care sector, ZEUS Scientific serves clinical laboratories and healthcare providers seeking reliable serology and diagnostic capabilities. The business became part of the Sebia corporate group in 2022, reflecting a broader diagnostic platform. In 2023, it introduced the Borrelia Modified Two-Tiered Testing algorithm, which received FDA clearance to improve early detection of Lyme disease. The company's ongoing product development underscores a focus on autoimmune and infectious disease diagnostics, alongside emerging cardiovascular risk tools.

Sign up for free to view info

Company overview Employee directory